In adult patients with CKD associated with T2D
In tissues such as kidney, heart, and blood vessels, blocks:
Has a high potency and selectivity for the mineralocorticoid receptor
Has no relevant affinity for androgen, progesterone, estrogen, and glucocorticoid receptors
KERENDIA is indicated to reduce the
risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D)
Measure serum potassium periodically during treatment with KERENDIA and adjust dose accordingly. More frequent monitoring may be necessary for patients at risk for hyperkalemia, including those on concomitant medications that impair potassium excretion or increase serum potassium
Please read the Prescribing Information for KERENDIA.
References: 1. KERENDIA (finerenone) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals, Inc.; July 2021. 2. Alicic RZ, et al. Clin J Am Soc Nephrol. 2017;12(12):2032-2045. 3. Toth-Manikowski S, et al. J Diabetes Res. 2015;2015. doi:10.11552015/697010. 4. Alicic RZ, et al. Adv Chronic Kidney Dis. 2018;25(2):181-191. 5. Tesch GH, et al. Front Pharmacol. 2017;8:313. doi:10.3389/fphar.2017.00313. 6. Thomas M, et al. Nat Rev Dis Primers. 2015;1:15018. doi:10.1038/nrdp.2015.18.